Trevi Therapeutics (NASDAQ:TRVI) Sets New 1-Year High – Still a Buy?

Trevi Therapeutics, Inc. (NASDAQ:TRVI)’s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $20.15 and last traded at $19.50, with a volume of 5526120 shares trading hands. The stock had previously closed at $17.95.

Analyst Upgrades and Downgrades

TRVI has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday, May 6th. Stifel Nicolaus set a $30.00 price objective on shares of Trevi Therapeutics in a report on Friday, May 8th. Morgan Stanley reaffirmed an “overweight” rating and issued a $20.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Monday, April 20th. Finally, D. Boral Capital reiterated a “buy” rating and set a $19.00 price target on shares of Trevi Therapeutics in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Trevi Therapeutics presently has an average rating of “Buy” and a consensus price target of $22.67.

Trevi Therapeutics Stock Up 8.6%

The business has a fifty day simple moving average of $15.23 and a 200-day simple moving average of $13.04. The firm has a market cap of $2.77 billion, a P/E ratio of -60.94 and a beta of 1.00.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). On average, sell-side analysts anticipate that Trevi Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Hilton Head Capital Partners LLC increased its stake in Trevi Therapeutics by 32.6% during the 1st quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company’s stock valued at $51,000 after purchasing an additional 1,044 shares in the last quarter. AlphaCentric Advisors LLC boosted its position in Trevi Therapeutics by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 23,970 shares of the company’s stock worth $286,000 after purchasing an additional 1,303 shares during the last quarter. Kennedy Capital Management LLC grew its position in Trevi Therapeutics by 2.4% during the fourth quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock valued at $704,000 after buying an additional 1,336 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Trevi Therapeutics by 32.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock valued at $78,000 after acquiring an additional 1,523 shares during the period. Finally, Oppenheimer & Co. Inc. increased its position in Trevi Therapeutics by 2.1% in the fourth quarter. Oppenheimer & Co. Inc. now owns 100,698 shares of the company’s stock worth $1,261,000 after buying an additional 2,030 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.